Stols-Gonçalves D,Hovingh GK,Nieuwdorp M,Holleboom AG .2019 .NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Trends Endocrinol Metab TEM. , 08(12) : 891-902.
Altaf B,Rehman A,Jawed S,Raouf A .2020 .Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients. Pak J Med Sci, 10(3) : 1674-390.
Lonardo A,Nascimbeni F,Mantovani A,Targher G .2017 .. atherosclerosis and NASH: Cause or consequence? J Hepatol, 09(2) : 335-352.
Targher G,Bertolini L,Padovani R,Rodella S,Tessari R,Zenari L .2007 .Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 10(5) : 2247-1218.
Teng ML,Ng CH,Huang DQ,Chan KE,Tan DJ,Lim WH .2022 .Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol, 0365(Suppl) : S32-S42.
LB VanWagner .2018 .New insights into NAFLD and subclinical coronary atherosclerosis. J Hepatol, 01(5) : 890-892.
Abdallah LR,De Matos RC,Souza E,Vieira-Soares YPDM,MullerMachado D,Pollo-Flores G,P G .2020 .Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis. Curr Atheroscler Rep, 10(1) : .
Cazac GD,Lăcătu-u CM,Mihai C,Grigorescu ED,Onofriescu A,Mihai BM .2022 .New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. , 10(8) : 1189.
Nishihara T,Miyoshi T,Ichikawa K,Osawa K,Nakashima M,Miki T .2022 .Association of Oxidized Low-Density Lipoprotein in Nonalcoholic Fatty Liver Disease with High-Risk Plaque on Coronary Computed Tomography Angiography: A Matched Case-Control Study. J Clin Med, 10(10) : 2838.
Starekova J,Hernando D,Pickhardt PJ,Reeder SB .2021 .Quantification of Liver Fat Content with CT and MRI: State of the Art. Radiology, 10(2) : 250-262.
Wells MM,Li Z,Addeman B,McKenzie CA,Mujoomdar A,Beaton M,Hepatol J Gastroenterol .2016 .Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. , 10 : .
Dendl LM,Schreyer AG .2012 .. Herausforderung? Radiol, 10(8) : 745-752.
Lawrence DA,Oliva IB,Israel GM .2012 .Detection of hepatic steatosis on contrast-enhanced CT images: diagnostic accuracy of identification of areas of presumed focal fatty sparing. Am J Roentgenol, 10(1) : 44-47.
Poyraz N,Ozer H,Baloglu I,Kadıyoran C,Yılmaz PD,Sertdemir AL .2022 .Liver-Spleen Ratio: Can It Be Used for the Prediction of Coronary Artery Disease?. Anatol J Cardiol, 10(10) : 762-770.
Tokushige K,Ikejima K,Ono M,Eguchi Y,Kamada Y,Itoh Y,Gastroenterol J .2021 .Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. , 10(11) : 951-963.
Finney AC,Das S,Kumar D,McKinney MP,Cai B,Yurdagul A .2023 .The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Front Cardiovasc Med, 10 : 1116861.
Shi W,Li G,Cui Z,Zhang D,Wang W,Zhao X .2021 .Study on the Relationship between Liver/Spleen CT Value Ratio and NonAlcoholic Fatty Liver with Atherosclerotic Plaque. J Clin Radiol, 02(2) : 227-281.
Yang Q,Wang Z,Huang Z,Zhang S,Xie Y,Wang X .2022 .Evaluation of Aortic Distensibility in Patients with Nonalcoholic Fatty Liver Using CT. Curr Med Imaging, 10(8) : 883-887.
Hideo-Kajita A,Garcia-Garcia HM,Wopperer SB,Freire AFD,Ozaki Y,Cavalcante R .2020 .Correlation between computed tomography adapted leaman score and computed tomography liver and spleen attenuation parameters for non-alcoholic fatty liver disease as well as respective inflammatory mediators. Int J Cardiovasc Imaging, 10(12) : 2383-2391.
Zhao J,Fan H,Wang T,Yu B,Mao S,Wang X .2022 .TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc Diabetol, 10(1) : 123.
Li H,Yu XH,Ou X,Ouyang XP,Tang CK .2021 .Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Prog Lipid Res, 10 : 101109.
Wójcik-Cichy K,Koślińska-Berkan E,Piekarska A .2018 .The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol, 10(1) : 1-6.
Heeren J,Scheja L .2021 .Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab, 10 : 101238.
Tanase DM,Gosav EM,Petrov D,Jucan AE,Lacatusu CM,Floria M .2053 .Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. , 10(11) : .
Peters KM,Wilson RB,Borradaile NM .2018 .Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis. Curr Opin Lipidol, 10(5) : 417-422.